Javascript must be enabled to continue!
Survey of Australians on Giving Effectively: Research Report
View through CrossRef
We conducted the online Survey of Australians on Giving Effectively (SAGE) of 1,059 Australians in May 2024 to investigate Australians’ attitudes towards effective charitable giving - that is, giving to charities and programs that do more good, per dollar. Australians think charity impact and effectiveness are important, with 9 in 10 preferring to donate to charities with clear, measurable impact; 8 in 10 demanding that charities be accountable for the impact of their work and the effectiveness of their programs; and 8 in 10 willing to switch their donation to a highly effective charity. Australians have an unmet need for information on charity effectiveness, with 3 in 10 Australians confident that their most recent donation had a lot of impact; transparency and evidence of impact being more important factors for charity choice than overheads and innovation; and half of donors researching a charity before donating. When asked to estimate the difference between the ‘best’ and ‘average’ global health charity programs, Australians thought the best program was 1.44x as effective, when experts estimate the actual difference to be 10 - 100x. Providing Australians with independent, trusted information on charity effectiveness could help align their donation decisions with their values, maximising the impact of the $13B spent on charity in Australia each year.
Title: Survey of Australians on Giving Effectively: Research Report
Description:
We conducted the online Survey of Australians on Giving Effectively (SAGE) of 1,059 Australians in May 2024 to investigate Australians’ attitudes towards effective charitable giving - that is, giving to charities and programs that do more good, per dollar.
Australians think charity impact and effectiveness are important, with 9 in 10 preferring to donate to charities with clear, measurable impact; 8 in 10 demanding that charities be accountable for the impact of their work and the effectiveness of their programs; and 8 in 10 willing to switch their donation to a highly effective charity.
Australians have an unmet need for information on charity effectiveness, with 3 in 10 Australians confident that their most recent donation had a lot of impact; transparency and evidence of impact being more important factors for charity choice than overheads and innovation; and half of donors researching a charity before donating.
When asked to estimate the difference between the ‘best’ and ‘average’ global health charity programs, Australians thought the best program was 1.
44x as effective, when experts estimate the actual difference to be 10 - 100x.
Providing Australians with independent, trusted information on charity effectiveness could help align their donation decisions with their values, maximising the impact of the $13B spent on charity in Australia each year.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Reclaiming the Wasteland: Samson and Delilah and the Historical Perception and Construction of Indigenous Knowledges in Australian Cinema
Reclaiming the Wasteland: Samson and Delilah and the Historical Perception and Construction of Indigenous Knowledges in Australian Cinema
It was always based on a teenage love story between the two kids. One is a sniffer and one is not. It was designed for Central Australia because we do write these kids off there. N...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...

